
Lary Robinson/moffitt.org
Apr 6, 2025, 09:05
Moffitt Trial Explores CIZ1B Blood Test for Early Lung Cancer Detection – Cizzle Bio, Inc.
Cizzle Bio, Inc. shared a post on LinkedIn:
“Clinical insight meets innovation.
Cizzle Bio, Inc. is proud to feature expert commentary from Dr. Lary Robinson of Moffitt Cancer Center in our latest Clinical Thought Leadership blog post. Learn how the CIZ1B biomarker-based blood test is being evaluated in a new clinical trial focused on advancing early detection and improving patient outcomes in lung cancer.
Read the full post.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 6, 2025, 08:25
Apr 6, 2025, 07:44
Apr 6, 2025, 07:34